TDM1

DRUG2 trials

Sponsors

Institut du Cancer de Montpellier - Val d'Aurelle, David Garcia Cinca

Conditions

HER2-positive Breast CancerMammary Cancer

Phase 1

Patients With Brain Metastases From HER2-positive Breast Cancer

CompletedNCT02135159

Institut du Cancer de Montpellier - Val d'AurelleHER2-positive Breast Cancer

Start: 2014-02-28End: 2017-03-31Updated: 2017-08-14

Phase 2

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Not yet recruitingNCT04301375

David Garcia CincaMammary Cancer

Start: 2020-06-15End: 2027-07-15Target: 27Updated: 2020-03-10

Related Papers

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response

Journal of Breast Cancer2024-01-0112 citations